TY  - CONF
AU  - Raimondi, A.
AU  - Morano, F.
AU  - Trarbach, T.
AU  - Karthaus, M.
AU  - Lonardi, S.
AU  - Fruehauf, S.
AU  - Cremolini, C.
AU  - Graeven, U.
AU  - Bittoni, A.
AU  - Mueller, L.
AU  - Bianchi, A. Sartore
AU  - Aranda, E.
AU  - Boige, V.
AU  - Stintzing, S.
AU  - Di Bartolomeo, M.
AU  - Koenig, A.
AU  - Pietrantonio, F.
AU  - Modest, D.
PY  - 2022
DO  - 10.1016/j.annonc.2022.04.420
SN  - 0923-7534
UR  - http://hdl.handle.net/10668/21914
T2  - Annals of oncology
AB  - Background: In metastatic colorectal cancer (mCRC), after a first-line induction with doublet/triplet chemotherapy plus bevacizumab, fluoropyrimidine+bevacizumab is the recommended maintenance option. The combination of anti-EGFR agents and...
LA  - en
PB  - Elsevier
KW  - Panitumumab
KW  - Bevacizumab
KW  - Proto-oncogene proteins B-raf
KW  - Humans
KW  - Progression-free survival
KW  - Colorectal neoplasms
KW  - Colonic neoplasms
KW  - Rectal neoplasms
TI  - Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials
TY  - conference output
VL  - 33
ER  -